Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
Research Feed
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage
Does a once-daily single pill containing three low-dose antihypertensive agents (telmisartan, amlodipine, indapamide) reduce the risk of first recurrent stroke in patients with a history of intracerebral hemorrhage compared to standard care alone?
Implication: Warrants low-dose triple pill in post-ICH BP management; confirms causal role of BP reduction in preventing recurrent stroke.
“Meaningful blood pressure control after intracerebral hemorrhage requires a coordinated, systemwide commitment that integrates team-based care, expanded access to medication, and real-time monitoring to bridge the gap between clinic visits and daily management. Beyond the primary care office, eve...”
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation
Does pulsed field ablation improve treatment success compared to antiarrhythmic-drug therapy in patients with previously untreated persistent atrial fibrillation?
Implication: Supports first-line PFA over AAD in persistent AF; challenges guidelines recommending initial drug trial before ablation.
“These findings have implications for clinical practice, for guidelines, and for insurance coverage because “there’s a lot of people that are dissuading us from doing persistents because it’s lower yield,” Tung said.”
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation
Does device-based left atrial appendage closure prevent a composite of cardiovascular death, stroke, or systemic embolism compared to NOAC therapy in patients with atrial fibrillation who are suitable candidates for anticoagulation?
Implication: Supports LAAC as NOAC alternative in suitable AF patients; extends prior warfarin evidence to current standard therapy.
“In patients with nonvalvular atrial fibrillation suitable for anticoagulation, left atrial appendage closure using the Watchman FLX device, at 3 years was noninferior to NOACs for the composite primary endpoint [of] cardiovascular death, stroke, and systemic embolization, and significantly reduced clinically relevant nonprocedural bleeding.”
Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation
Does left atrial appendage closure reduce the composite of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death compared to physician-directed best medical care in patients with atrial fibrillation at high risk for stroke and bleeding?
Implication: Reinforces medical therapy as standard in high-bleed-risk AF; challenges positive prior LAAO trials and guidelines.
“In general, the benefit from any percutaneous intervention in cardiology is often the greatest with regard to the most acute or life-threatening problem the patient is facing. In contrast, in clinical situations in which the patient’s life is not directly at risk and the symptoms are controllable by medical treatment, conservative management should always be considered to be an equally effective alternative.”
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction
Does discontinuation of beta-blocker therapy prove noninferior to continuation in stable patients with LVEF ≥40% and no heart failure who received beta-blockers for at least 1 year post-MI?
Implication: May warrant deprescribing in stable post-MI patients with preserved EF; challenges decades of guideline-endorsed lifelong continuation.
“At subsequent visits, it’s always an opportunity to revisit [and ask] can we reduce this pill burden? This study demonstrated in a more definitive fashion than the ABYSS study that yes, at 1 year, it is safe in patients with normal ejection fraction and no atrial fibrillation to stop that beta-bl...”
Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention
Does elective left ventricular unloading with a microaxial flow pump improve clinical outcomes in patients with severe left ventricular dysfunction and extensive coronary artery disease undergoing complex PCI?
Implication: Routine elective LV unloading cannot be recommended in high-risk PCI; challenges observational data and smaller trials suggesting benefit.
“The results were 'surprising because the whole premise of LV unloading was that it protects the heart.' But we found that patients assigned to LV unloading had more damage to the [LV] than those assigned to standard care. Our findings strongly suggest that we shouldn't be using this device routinely without more evidence of benefit.”
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Implication: Adopt apoB/Lp(a) personalization and lower LDL-C targets in practice; extends 2018 guidance with post-FOURIER/ODYSSEY evidence.
This Week in Cardiology: Apr 10 2026 This Week in CardiologyUltrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
Does ultrasound-facilitated, catheter-directed fibrinolysis with alteplase plus anticoagulation reduce the composite of pulmonary embolism-related death, cardiorespiratory decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days in patients with acute, intermediate-risk pulmonary embolism compared to anticoagulation alone?
Implication: Supports use in intermediate-high risk PE; extends smaller trials as first large RCT powered for clinical outcomes.
“This trial shows that a catheter intervention can indeed be effective and improve the prognosis for patients with severe PE and elevated risk of early death or life-threatening complications. If the right patients are selected for this procedure, it can prevent patients from deteriorating and it can do so at an acceptably low risk of bleeding complications.”
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
Does targeting an LDL cholesterol level of less than 55 mg/dL reduce cardiovascular events compared to targeting less than 70 mg/dL in patients with atherosclerotic cardiovascular disease?
Implication: Favors LDL <55 mg/dL target in ASCVD; extends FOURIER/ODYSSEY with contemporary RCT evidence supporting lower-is-better.
“This is really saying that 55 is our new goal and we need to really embrace that and work hard to get patients to that goal.”
Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial
Is left-bundle branch area pacing non-inferior to biventricular pacing for achieving a positive CRT response at 6 months in patients with guideline-based CRT indications and left-bundle branch block?
Implication: LBBAP-CRT not noninferior to BiVP-CRT in typical LBBB; leaves open its routine adoption pending further randomized evidence.
“We now have randomized data showing that [LBBAP] is a very credible CRT option, with procedural advantages in some settings and clinical outcomes that are at least broadly comparable to BiV-CRT in selected populations. But I would still be cautious about overinterpreting the current evidence. These trials are important, but they do not yet justify a one-size-fits-all conclusion that LBBAP should replace conventional CRT across the board.”